Astex Market Share Analysis for August 2026

Health > Biotechnology and Pharmaceuticals

Domainastx.com

Year Founded1999

Employees51 - 200

Annual Revenue$50M - $75M

Astex

Astex (including company regionals)

astx.com

See more website traffic and engagement information

Astex Revenue up to August 2026 is 50M - 75M

revenue generated by Astex top domains

Astex top domains revenue over 3 years

Revenue for Astex top domains

astx.com50M - 75M

See more with Sales Intelligence

Total visits to Astex's top domains

Understand Astex market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

astx.com9.3K

See more with Sales Intelligence

Avg. visit duration in Astex's top domains

Analyze Astex engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

astx.com00:01:09

See more with Sales Intelligence

Avg. pageviews on Astex's top domains

See how Astex keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

astx.com2.66

See more with Sales Intelligence

Astex top competitors by domain

Top similar sites in August 2026, ranked by their affinity

afnm.comCompany NameAffinium Pharmaceuticals, Inc.Employees51 - 200HQUnited States, Texas, AustinAnnual revenue$10M - $15MTotal visits--Health > Biotechnology and Pharmaceuticals

Top technologies used by Astex

These are the website technologies, by industry, used by Astex top domains

Audio Video Media (2)

YouTube

Content Management System (2)

WordPress

Marketing (2)

Google Marketing Platform

Mobile (2)

Meta Viewport

More Technologies

8

See all

News & Signals from Astex

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAstx is developing KRAS inhibitors for cancer on Jul 1st '24.Astex is also partnering with MSD and Taiho on KRAS inhibitors for cancer, headed by oral KRAS G12C inhibitor calderasib (MK-1084), which started a phase 3 programme in 2024 in non-small cell lung cancer (NSCLC) and colorectal cancer.

NewsAstx is developing breast cancer therapy on Jul 6th '26.At the same time, Genentech is teaming up with Astex Pharmaceuticals to develop an investigational breast cancer therapy in a deal that could top $490 million, according to a Monday release.

NewsAstx partnered with Genentech on Jul 6th '26.Astex announces exclusive research collaboration and license agreement with Genentech for breast cancer therapy program.